Medication guide for the perioperative management of oral antineoplastic agents in cancer patients.
Administration, Oral
Angiogenesis Inhibitors
/ administration & dosage
Anticoagulants
/ administration & dosage
Antineoplastic Agents
/ administration & dosage
Dose-Response Relationship, Drug
Hemorrhage
/ chemically induced
Humans
Neoplasms
/ drug therapy
Perioperative Care
/ methods
Wound Healing
/ drug effects
Cancer
oncology
oral antineoplastic agents
perioperative
posology
reconciliation
safety
surgery
Journal
Expert opinion on drug safety
ISSN: 1744-764X
Titre abrégé: Expert Opin Drug Saf
Pays: England
ID NLM: 101163027
Informations de publication
Date de publication:
Jan 2022
Jan 2022
Historique:
pubmed:
7
8
2021
medline:
20
1
2022
entrez:
6
8
2021
Statut:
ppublish
Résumé
Oral antineoplastic agents (OAAs) are high-risk drugs that may increase the risk of bleeding, difficulty in wound healing, or produce alterations in coagulation and/or platelet aggregation. These aspects had to be highly considered throughout the entire perioperative process. Our aim was to create a comprehensive management medication guide based on reconciliation and dose adjustment recommendations for OAAs in patients undergoing a surgical intervention. We analyzed all OAAs approved by the EMA in November 2020. We assessed data related to dose adjustment, drug reconciliation, coagulation disturbances, or anticoagulant interactions from the FDA and EMA summary of product characteristics. We analyzed 67 OAAs. We identified that 51 (76.2%) OAAs can produce alteration in the platelet count, 12 (17.9%) affect the wound healing and recovery process, and 32 (47.8%) require control and monitoring in case of combination with anticoagulants. Only 13 (19.4%) OAAs, most of them antiangiogenics, have specific recommendations for temporary suspension before surgery. Most OAAs require perioperative monitoring. This review can serve as an easy (simple, effective) tool to help healthcare professionals involved in patient care to manage OAAs during the perioperative process.
Sections du résumé
BACKGROUND
BACKGROUND
Oral antineoplastic agents (OAAs) are high-risk drugs that may increase the risk of bleeding, difficulty in wound healing, or produce alterations in coagulation and/or platelet aggregation. These aspects had to be highly considered throughout the entire perioperative process. Our aim was to create a comprehensive management medication guide based on reconciliation and dose adjustment recommendations for OAAs in patients undergoing a surgical intervention.
RESEARCH DESIGN AND METHODS
METHODS
We analyzed all OAAs approved by the EMA in November 2020. We assessed data related to dose adjustment, drug reconciliation, coagulation disturbances, or anticoagulant interactions from the FDA and EMA summary of product characteristics.
RESULTS
RESULTS
We analyzed 67 OAAs. We identified that 51 (76.2%) OAAs can produce alteration in the platelet count, 12 (17.9%) affect the wound healing and recovery process, and 32 (47.8%) require control and monitoring in case of combination with anticoagulants. Only 13 (19.4%) OAAs, most of them antiangiogenics, have specific recommendations for temporary suspension before surgery.
CONCLUSIONS
CONCLUSIONS
Most OAAs require perioperative monitoring. This review can serve as an easy (simple, effective) tool to help healthcare professionals involved in patient care to manage OAAs during the perioperative process.
Identifiants
pubmed: 34357828
doi: 10.1080/14740338.2021.1965990
doi:
Substances chimiques
Angiogenesis Inhibitors
0
Anticoagulants
0
Antineoplastic Agents
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM